PharmaCyte Biotech (PMCB) Assets (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Assets of $46.8 million for Q2 2026, down 15.25% year-over-year from $55.2 million in Q2 2025, and down 16.32% quarter-over-quarter from $55.9 million in Q1 2026.
PharmaCyte Biotech (PMCB) Assets (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Assets for 16 consecutive years, with $46.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets fell 15.25% year-over-year to $46.8 million; the TTM figure through Apr 2026 stood at $46.8 million (down 15.25% YoY), while the FY2026 annual figure was $46.8 million, down 15.25% from the prior year.
- Assets eased to $46.8 million in Q2 2026 per PMCB's latest filing, from $55.9 million in the prior quarter.
- Across five years, Assets topped out at $91.9 million in Q1 2022 and bottomed at $43.8 million in Q1 2025.
- Historically, Assets has averaged $67.9 million across 5 years, with a median of $70.8 million in 2024.
- Annual changes were most pronounced in 2022 — Assets jumped 1216.56% — and 2025, when it plunged 38.58%.
- PharmaCyte Biotech's Assets stood at $82.3 million in 2022, then fell by 4.21% to $78.9 million in 2023, then sank by 30.15% to $55.1 million in 2024, then rose by 1.59% to $56.0 million in 2025, then declined by 16.48% to $46.8 million in 2026.
- Business Quant data shows PMCB's Assets at $46.8 million in Q2 2026, $55.9 million in Q1 2026, and $56.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 46.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 46.75 Mn |
| Jan 31, 2026 | 55.87 Mn |
| Oct 31, 2025 | 55.98 Mn |
| Jul 31, 2025 | 45.11 Mn |
| Apr 30, 2025 | 55.17 Mn |
| Jan 31, 2025 | 43.83 Mn |
| Oct 31, 2024 | 55.10 Mn |
| Jul 31, 2024 | 70.19 Mn |
| Apr 30, 2024 | 59.90 Mn |
| Jan 31, 2024 | 71.36 Mn |
| Oct 31, 2023 | 78.88 Mn |
| Jul 31, 2023 | 79.88 Mn |
| Apr 30, 2023 | 73.28 Mn |
| Jan 31, 2023 | 77.95 Mn |
| Oct 31, 2022 | 82.35 Mn |
| Jul 31, 2022 | 87.39 Mn |
| Apr 30, 2022 | 90.62 Mn |
| Jan 31, 2022 | 91.94 Mn |
| Oct 31, 2021 | 92.31 Mn |
| Jul 31, 2021 | 6.64 Mn |